Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2025
DOI: 10.1111/ddg.15948 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2025. Verfasst von Christoph Zeyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate m…. Hauptthemen laut MEDLINE: Psoriasis, Mass Screening, Latent Tuberculosis, Practice Patterns, Physicians'. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited. To better evaluate the risk of TB reactivation, data on LTBI patients exposed to these medications without preventive TB therapy are necessary. This study was conducted as part of the update of the European and German psoriasis guidelines aimed to assess current LTBI screening and preventive treatment practices. Patients and Methods An online survey was distributed via German, European and international dermatological societies, yielding 326 complete responses. Results LTBI screening was performed by 45% of respondents before MTX initiation and 95% before IL‐17/IL‐23/IL‐12/23p40 inhibitors. Preventive TB therapy was initiated “always” or “almost always” in 38% of MTX cases and “never” or “almost never” in 31%. For IL‐17/IL‐23/IL‐12/23p40 inhibitors, preventive TB therapy was used in 66% of cases “always” or “almost always,” 16% case‐by‐case and 9% “never” or “almost never.” Conclusions LTBI screening and preventive TB therapy for MTX lack standardization. While screening is common for IL‐17/IL‐23/IL‐12/23p40 inhibitors, a significant proportion of LTBI patients receive these treatments without preventive TB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,…
- German Central Committee against Tuberculosis (DZK), Berlin, Germany.
ORCID-Profile: Christoph Zeyen, Ruben Heuer
Zitieren
APA
Zeyen, C., Heuer, R., Haecker, B., Schaberg, T., & Nast, A. (2025). Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15948
Vancouver
Zeyen C, Heuer R, Haecker B, Schaberg T, Nast A. Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2025. doi:10.1111/ddg.15948
BibTeX
@article{Zeyen2025,
author = {Zeyen, Christoph and Heuer, Ruben and Haecker, Brit and Schaberg, Tom and Nast, Alexander},
title = {Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2025},
doi = {10.1111/ddg.15948}
}
EUVIMED